Lyka Labs Limited
Lyka Labs Limited is an Indian listed company in the Pharmaceuticals & Biotechnology industry (Healthcare sector), traded under NSE: LYKALABS and BSE: 500259 (ISIN INE933A01014).
It has a market capitalisation of ₹307 crore, a last close of ₹86.04 on 2026-10-19, a one-year return of -8.8%.
Valuation: a price-to-book ratio of 3.32x, a dividend yield of 0.0%.
Profitability: return on equity of -10.2%, return on capital employed of -6.8%, an operating margin of -2.0%.
Growth: sales growth of 11.3% a year over three years.
Balance sheet and ownership: debt-to-equity of 0.52x, promoter holding of 58.5%.
| Metric | Value |
|---|---|
| Market capitalisation | 307 |
| Last close | ₹86.04 |
| P/B | 3.32x |
| Dividend yield | 0.0% |
| ROE (FY) | -10.2% |
| ROCE (FY) | -6.8% |
| Operating margin (TTM) | -2.0% |
| Sales growth, 3-year CAGR | 11.3% |
| Debt / equity | 0.52x |
| Promoter holding | 58.5% |
| 1-year return | -8.8% |
Loading the live page with the price chart, financial history, shareholding and recent filings. Data is end-of-day and rebuilt nightly; nothing here is investment advice. Financial statements · What each metric means